Cardiff Oncology, Inc. (CRDF)
NASDAQ:CRDF
Want to see CRDF full AI Analyst Report?
CRDF Stock Chart & Stats
$1.80
-$0.21(-4.99%)
At close: 4:00 PM EST
$1.80
-$0.21(-4.99%)
Day’s Range― - ―
52-Week Range$1.35 - $4.56
Previous CloseN/A
Volume446.20K
Average Volume (3M)1.30M
Market Cap
$102.55M
Enterprise Value$122.00M
Total Cash (Recent Filing)$46.06M
Total Debt (Recent Filing)$646.00K
Price to Earnings (P/E)―
Beta1.27
Next Earnings
Jul 30, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.67
Shares Outstanding68,369,896
10 Day Avg. Volume2,143,555
30 Day Avg. Volume1,298,955
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)4.14
Price to Sales (P/S)316.73
P/FCF Ratio-4.95
Enterprise Value/Market Cap1.19
Enterprise Value/Revenue232.39
Enterprise Value/Gross Profit-11.04
Enterprise Value/Ebitda-2.67
Forecast
1Y Price Target
$6.00Price Target Upside233.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.68
Revenue Forecast (FY)$239.44K
Bulls Say, Bears Say
Bulls Say
Phase 2 Efficacy And Clear Regulatory PathRobust randomized Phase 2 results with a 72% objective response rate, favorable safety, and an agreed end-of-Phase 2 path materially strengthen the development thesis. This creates a durable registrational roadmap (Phase 3 designed for accelerated then full approval), improving the probability of a sustainable commercial opportunity in first-line RAS‑mutant mCRC and related indications over the next 2–6 months and beyond.
Conservative Leverage And Low DebtVery low reported debt materially reduces near-term solvency risk and provides financial flexibility for a pre-revenue biotech. This durable structural strength lowers the risk of covenant-driven disruptions, gives management optionality for partnering or staged financing, and buys runway flexibility while clinical milestones are pursued over the medium term.
Seasoned Leadership AppointedBringing in executives with commercial, financing and clinical development experience is a durable operational positive. Improved capital markets and clinical execution capabilities increase odds of efficient Phase 3 planning, regulatory interactions, and fundraising, reducing execution risk around onvansertib during the critical development and financing window ahead.
Bears Say
Persistent Negative Cash FlowSustained multi‑tens‑of‑millions cash burn versus negligible revenue is a structural weakness. Over the coming months the company will likely need external capital to fund trials and operations, which increases dilution risk, can constrain strategic choices, and adds execution uncertainty if financing terms deteriorate or financing windows narrow.
Material IP And License DisputeOngoing litigation and a license termination threat create persistent strategic and operational risk. If the dispute impairs Cardiff’s rights to onvansertib, it could delay or block pivotal trials, complicate regulatory filings, and deter partners or investors. This structural uncertainty materially increases program and value risk over the medium term.
Minimal Revenue And Large LossesThe company remains pre‑commercial with negligible revenue and deep operating losses, reflecting poor operating leverage. Continued declines in revenue and negative margins limit internal funding capacity, heighten dependency on external financing, and reduce resilience to trial setbacks—fundamental constraints on long‑term sustainability until commercialization or major partnership occurs.
Cardiff Oncology News
CRDF FAQ
What was Cardiff Oncology, Inc.’s price range in the past 12 months?
Cardiff Oncology, Inc. lowest stock price was $1.35 and its highest was $4.55 in the past 12 months.
What is Cardiff Oncology, Inc.’s market cap?
Cardiff Oncology, Inc.’s market cap is $102.55M.
When is Cardiff Oncology, Inc.’s upcoming earnings report date?
Cardiff Oncology, Inc.’s upcoming earnings report date is Jul 30, 2026 which is in 52 days.
How were Cardiff Oncology, Inc.’s earnings last quarter?
Cardiff Oncology, Inc. released its earnings results on May 14, 2026. The company reported -$0.18 earnings per share for the quarter, missing the consensus estimate of -$0.135 by -$0.045.
Is Cardiff Oncology, Inc. overvalued?
According to Wall Street analysts Cardiff Oncology, Inc.’s price is currently Undervalued.
Does Cardiff Oncology, Inc. pay dividends?
Cardiff Oncology, Inc. does not currently pay dividends.
What is Cardiff Oncology, Inc.’s EPS estimate?
Cardiff Oncology, Inc.’s EPS estimate is -0.12.
How many shares outstanding does Cardiff Oncology, Inc. have?
Cardiff Oncology, Inc. has 68,369,896 shares outstanding.
What happened to Cardiff Oncology, Inc.’s price movement after its last earnings report?
Cardiff Oncology, Inc. reported an EPS of -$0.18 in its last earnings report, missing expectations of -$0.135. Following the earnings report the stock price went down -3.468%.
Which hedge fund is a major shareholder of Cardiff Oncology, Inc.?
Currently, no hedge funds are holding shares in CRDF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cardiff Oncology Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.00 (233.33% Upside)
$6.00 (233.33% Upside)
Blogger Sentiment
Bullish
CRDF Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 10.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 1.5%
Last 30 Days ▼ 1.5%
News Sentiment
Neutral
Bullish news 59%
Bearish news 57%
Bearish news 57%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-58.56%
12-Months-Change
Fundamentals
Return on Equity
-95.51%
Trailing 12-Months
Asset Growth
-42.02%
Trailing 12-Months
Company Description
Cardiff Oncology, Inc.
Cardiff Oncology, Inc., a clinical-stage biotechnology firm located in San Diego, California, is dedicated to developing innovative medical treatments for cancer patients. Its lead therapeutic agent is onvansertib, an oral and selective inhibitor of Polo-like Kinase 1 (PLK1), which is being investigated for various anti-cancer applications, including clinical trials for metastatic colorectal cancer. The company's pipeline further includes CY140, an inhibitor targeting PLK1, PLK2, and PLK3, currently progressing through Phase 1/2 studies for both solid tumors and leukemias. Additionally, Cardiff Oncology is advancing TROV-054 in Phase 1b/2 trials, exploring its combination with FOLFIRI and bevacizumab, and TROV-053 in a Phase II clinical trial, where it is being assessed alongside Zytiga for metastatic castration-resistant prostate cancer. Established in 1999, the company, which primarily supplies its pharmaceutical innovations to manufacturers, was originally known as Trovagene, Inc. It officially rebranded to Cardiff Oncology, Inc. in May 2012.
CRDF Stock 12 Month Forecast
Average Price Target
$6.00
▲(233.33% Upside)
Technical Analysis
Oncolytics Biotech
―
―
Avalo Therapeutics
―
Greenwich LifeSciences
―
Molecular Partners
―
Pyxis Oncology
―
Ownership Overview
4.18% Insiders
7.95% Mutual Funds
12.79% Other Institutional Investors
66.93% Public Companies and Individual Investors